This study sought to investigate the effects of interventional renal sympathetic denervation (RD) on cardiorespiratory response to exercise.
Background
RD reduces blood pressure at rest in patients with resistant hypertension.
Methods
We enrolled 46 patients with therapy-resistant hypertension as extended investigation of the Symplicity HTN-2 (Renal Denervation With Uncontrolled Hypertension) trial. Thirty-seven patients underwent bilateral RD and 9 patients were assigned to the control group. Cardiopulmonary exercise tests were performed at baseline and 3-month follow-up.
Results
In the RD group, compared with baseline examination, blood pressure at rest and at maximum exercise after 3 months was significantly reduced by 31 Ϯ 13/9 Ϯ 13 mm Hg (p Ͻ 0.0001) and by 21 Ϯ 20/5 Ϯ 14 mm Hg (p Ͻ 0.0001), respectively. Achieved work rate increased by 5 Ϯ 13 W (p ϭ 0.029) whereas peak oxygen uptake remained unchanged. Blood pressure 2 min after exercise was significantly reduced by 29 Ϯ 17/8 Ϯ 15 mm Hg (p Ͻ 0.001 for systolic blood pressure; p ϭ 0.002 for diastolic blood pressure). Heart rate at rest decreased after RD (4 Ϯ 11 beats/min; p ϭ 0.028), whereas maximum heart rate and heart rate increase during exercise were not different. Heart rate recovery improved significantly by 4 Ϯ 7 beats/min after renal denervation (p ϭ 0.009). In the control group, there were no significant changes in blood pressure, heart rate, maximum work rate, or ventilatory parameters after 3 months.
Conclusions
RD reduces blood pressure during exercise without compromising chronotropic competence in patients with resistant hypertension. Heart rate at rest decreased and heart rate recovery improved after the procedure. Renal sympathetic nerves are crucial for the development and maintenance of arterial hypertension by regulating renin release, tubular sodium reabsorption, and renal blood flow (1) . Afferent sympathetic nerves from the kidney contribute to regulation of whole-body sympathetic activity (2) . The ability to selectively denervate the renal efferent and afferent sympathetic nerves is available with a percutaneous, catheter-based application of endovascular radiofrequency energy (3) . A recently published multicenter, randomized trial proved the efficacy of catheter-based renal sympathetic denervation (RD) in patients with resistant hypertension (4). The procedure was also shown to reduce renal and central sympathetic activity and thereby to improve blood pressure and glucose metabolism (5, 6) . However, sympathetic nerve activity physiologically regulates the response to physical stress, leading to increased heart rate, cardiac output, blood pressure, and ventilation. The effects of RD on these functions have not been investigated so far. In particular, it is not known whether this new therapeutic approach has a negative impact on chronotropic competence and may therefore impair physical exercise capacity. Our study investigated the effects of RD on the cardiopulmonary response during cardiopulmonary exercise testing in patients with resistant hypertension.
Methods
Study subjects. Twenty-eight patients were included in the Symplicity HTN-2 (Renal Denervation With Uncontrolled Hypertension) trial in Homburg/Saar and Cologne (4). The current study was extended by including 18 patients with the same inclusion and exclusion criteria. Eligible patients were age Ն18 years and had an office blood pressure of Ն160 mm Hg (Ն150 mm Hg for type 2 diabetic patients), despite being treated with Ն3 antihypertensive drugs (including a diuretic), with no changes in medication for a minimum of 2 weeks prior to enrolment. Complete inclusion and exclusion criteria of the Symplicity HTN-2 trial were described elsewhere (4). The study was approved by the local ethics committees in accordance with the Declaration of Helsinki. Patients were treated between March 2009 and October 2010 with subsequent follow-up to 3 months. All patients gave written informed consent. Nine patients were randomly assigned to a control group and 37 to an RD group in a 1:3 ratio. The RD procedure was performed as described previously (4) . Cardiopulmonary exercise testing. Cardiopulmonary exercise testing (CPET) was performed in all patients after randomization (baseline) and after 3 months. Patients underwent symptom-limited CPET with breath-by-breath gas exchange analyses using an Innocor spiroergometry system (Innovision, Odense, Denmark) or a Masterscreen CPX (Viasys, Berlin, Germany). Patients performed bicycle exercise in a 45°semi-supine position lying on an ergometrics 99EL reclining ergometer (Ergoline Cardio-Systems, Bitz, Germany). The physician supervising the exercise testing was blinded to the randomization. Resting blood pressure was taken after the subject was sitting for at least 10 min. After adaptation to the mouthpiece at resting conditions, exercise work rate was increased continuously by 15 W/min (ramp protocol) followed by a recovery phase for 4 min. Heart rate and cardiac rhythm was continuously recorded with 12-lead electrocardiography throughout the procedure. Blood pressure was measured in 2-min intervals during CPET and the recovery period by an experienced physician using a manual sphygmomanometer. In each patient, maximum achieved work rate, peak oxygen consumption, oxygen uptake at the anaerobic threshold (AT), minute ventilation, VE/VCO 2 slope (ϭ minute ventilation -carbon dioxide output relationship), and the respiratory exchange ratio (ϭ carbon dioxide output -oxygen uptake relationship) were measured. The V-slope, ventilatory equivalents, and end-tidal pressure methods were used for determination of the AT (7). Both systolic blood pressure (SBP) and diastolic blood pressure (DBP) at recovery were defined as blood pressure 2 min after termination of exercise. Heart rate recovery (HRR) was defined as the reduction in heart rate from peak exercise to the heart rate 1 min after the cessation of exercise. Statistical analysis. Data are presented as mean Ϯ SD unless otherwise specified. Comparisons within groups were performed using the Pearson chi-square test for categorical variables and the Wilcoxon rank sum test or an unpaired t test for continuous variables where appropriate. For between-group changes, the repeated measures analysis of variance model was used, unless otherwise specified. All statistical analyses were performed with SPSS statistical software (version 12.0, SPSS Inc., Chicago, Illinois).
Results
Patients in the treatment and control groups were matched with regard to age, sex, blood pressure, and medication (Table 1) . Patients and treating physicians were instructed not to change antihypertensive medication during the study, and RD and CPET were performed without any serious adverse events in all patients.
Despite an intake of 5.7 Ϯ 1.4 antihypertensive drugs, resting blood pressure at baseline was 172 Ϯ 24/94 Ϯ 19 mm Hg in the intervention group and 166 Ϯ 23/90 Ϯ 7 mm Hg in the control group, respectively (p ϭ 0.507 for SBP, p ϭ 0.579 for DBP). Blood pressure at maximum exercise stage was 227 Ϯ 24/104 Ϯ 18 mm Hg without significant differences between the groups (p ϭ 0.970 for SBP; p ϭ 0.915 for DBP) ( Table 2) . At 3-month follow-up, resting blood pressure in the RD group was reduced by 31 Ϯ 19/9 Ϯ 13 mm Hg (p Ͻ 0.0001 for SBP and DBP), without significant changes in the control group (Fig. 1) . In patients who underwent RD, maximum achieved work rate was increased by 5 Ϯ 13 W (p ϭ 0.029), whereas blood pressure Peak oxygen uptake (VO 2 peak) was different between the groups at baseline and after 3 months. The peak respiratory exchange rate (RER) at 3 months was 1.06 in both groups, without any significant changes compared with the baseline values (p ϭ 0.082 in RD; p ϭ 0.468 in control), indicating a comparable subjects' effort stage. At baseline, VO 2 at the anaerobic threshold (VO 2 AT) was 12 Ϯ 2 ml/min/kg in the Values are mean Ϯ SD or n (%). *For comparison between groups, the Pearson chi-square test or Wilcoxon rank sum test was performed. ACE ϭ angiotensin-converting enzyme; ARB ϭ angiotensin receptor blocker; BMI ϭ body mass index; DBP ϭ diastolic blood pressure; eGFR ϭ estimated glomerular filtration rate; SBP ϭ systolic blood pressure. Values are mean Ϯ SD. *p value ϭ baseline versus 3-month follow-up. †p value ϭ renal denervation group versus control group. RER ϭ respiratory exchange rate; VE/VCO 2 ϭ minute ventilation -carbon dioxide output relation; VO 2 ϭ oxygen uptake; VO 2 AT ϭ oxygen uptake at anaerobic threshold; VO 2 peak ϭ peak oxygen uptake; other abbreviations as in Table 1 .
Resting and Exercise Measurements
RD group and 14 Ϯ 4 ml/min/kg in the control group. In the RD group, VO 2 AT was significantly lower in diabetic than in nondiabetic subjects (12 Ϯ 2 ml/min/kg vs. 13 Ϯ 2 ml/min/kg, p ϭ 0.045). After 3 months, a trend for an increased VO 2 AT was noticed in treated subjects (1 Ϯ 2 ml/min/kg; p ϭ 0.052). Other ventilatory parameters were not significantly different in both groups after 3 months (Table 2) .
RD reduced heart rate at rest by 4 Ϯ 11 beats/min compared with baseline values (p ϭ 0.028) (Fig. 3 ), in particular in nondiabetic patients (-7 Ϯ 11 beats/min vs. 0 Ϯ 10 beats/min in diabetic patients; p ϭ 0.037). The maximum achieved heart rate was not significantly different between the groups (Fig. 4) . Heart rate increase at different exercise levels was not impaired after RD (Fig. 5) . With a significant number of patients being on beta-blockers (91%), the prevalence of chronotropic incompetence (CI) defined as failure to achieve 80% of the maximum agepredicted heart rate (7), was 78% (n ϭ 28) in the treatment group and 44% (n ϭ 4) in the control group, respectively. At the 3-month visit, 1 additional patient in the control group suffered from CI during exercise (28 patients [76%] in RD, p ϭ 1.0; 5 patients [56%] in control subjects, p ϭ 0.317). One minute after exercise termination, heart rate decreased by 16 Ϯ 9 beats/min in the RD and by 22 Ϯ 9 beats/min in the control group without significant differences between groups (p ϭ 0.113). This HRR improved by 4 Ϯ 7 beats/min (p ϭ 0.009) 3 months after RD, whereas no changes were noted in the control group. Beside changes of resting heart rate and VO 2 AT, no significant differences between diabetic and nondiabetic patients in the RD group were found.
Discussion
Besides the known effect of RD on blood pressure at rest (3,4), our study showed for the first time that renal nerve ablation significantly reduces blood pressure during exercise with improvements in HRR without blood pressure dysregulation, ventilatory effects, or chronotropic incompetence. Cardiopulmonary exercise tests are sufficient and reproducible methods to investigate the neurovegetative response to physical strain (8) . Due to the reduction of central sympathetic activity by influencing renal afferent nerve activity, there might be the concern about impaired cardiovascular response during exercise after RD (9) .
Dynamic exercise is associated with a rise of cardiac output and a reduction in peripheral vascular resistance. As a consequence, SBP normally rises with increasing work rate and DBP remains the same or decreases slightly (10) . Blood pressure response to exercise can predict cardiovascular morbidity and mortality independent of resting values (11, 12) . A 21-year follow-up study showed that a SBP of Ͼ200 mm Hg at 100 W was associated with higher cardiovascular morality rates (13) . Herein, patients with resistant hypertension showed a rise of SBP of 55 mm Hg during exercise despite having a resting blood pressure of 172/94 mm Hg. Three months after RD, SBP was reduced Changes of Blood Pressure
Changes of blood pressure at rest, at maximum work rate, and at recovery for renal denervation (RD) and control (C) groups. Error bars are 95% confidence intervals. DBP ϭ diastolic blood pressure; SBP ϭ systolic blood pressure.
at all stages of exercise, without changes in concomitant drug treatment. Moreover, the relative change of SBP during exercise was maintained after RD, indicating a physiological blood pressure adaption to increasing work rates. SBP at 2 min after cessation of exercise decreased from 203 Ϯ 24 mm Hg at baseline to 174 Ϯ 20 mm Hg 3 months after RD. There is evidence that SBP after exercise provides prognostic information on cardiovascular morbidity (14, 15) . Hence, RD led to a significant reduction of blood pressure during exercise and recovery, without hypotensive response or inadequate blood pressure rise during exercise. Exercise capacity can be determined by maximum achieved work rate or by VO 2 peak. We observed a slight improvement of maximum work rate whereas VO 2 peak remained unchanged after RD. In severe hypertension, cardiac output can be limited by an excessive rise of SBP (11) . However, our patients showed no change of VO 2 peak, a surrogate parameter of maximal cardiac output during the study period. RD elevated AT, indicating an improved aerobic capacity. The respiratory exchange ratio, as a key parameter for inter-and intraindividual comparisons of exercise exhaustion (7), was Ͼ1.0, indicating a sufficient grade of patients' exhaustion without being different between both groups or having changed after 3 months. This provides evidence that the observed changes are not related to an increased or decreased level of effort or exhaustion in the follow-up examination. Furthermore, we did not observe changes of minute ventilation or ventilatory efficiency. Whereas normal values of VE/VCO 2 slope are considered Ͻ30, patients with heart failure can exceed this threshold by far (16, 17) . Although, chemosensitivity to carbon dioxide is influenced by sympathetic drive (18) , VE/VCO 2 slope was not changed after RD. However, ventilatory efficiency was 
Figure 3 Changes of HR
Changes of heart rate (HR) at rest, peak HR, and HR recovery (peak HR -HR 1 min after cessation of exercise) for RD and C groups. Error bars are 95% confidence intervals. bpm ϭ beats/min; other abbreviations as in Figure 1 . within normal limits in our study population. The effects of RD in patients with impaired ventilatory efficiency, such as heart failure, remain to be investigated. Herein, patients after RD showed a reduced heart rate at rest, in particular in nondiabetic patients. Heart rate is a predictor of cardiovascular mortality and morbidity in the general population, as well as in patients with hypertension and heart failure (19 -22) . The less pronounced effect of RD on heart rate reduction in diabetic patients may be explained by cardiac autonomic neuropathy (23) . CI represents an inadequate rise of heart rate in response to exercise and can be defined as failure to achieve 80% of the age-predicted maximal heart rate. In subjects without heart rate-limiting drugs, CI is associated with increased cardiovascular mortality (24) . There might be concerns that RD could possibly lead to a reduced heart rate response during exercise. However, heart rate adaption during exercise after RD was not impaired. Due to the prevalence of beta-blockers treatment, the observed prevalence of CI was high, but remained unchanged after ablation of the renal sympathetic nerves. In this study, we found significant improvement of HRR after cessation of exercise in the intervention group. HRR was identified as a predictor of mortality in healthy subjects and in patients with cardiovascular disease (25) (26) (27) . In patients without previous known cardiovascular disease, the relative risk of death was halved for a decrease by 9 beats/min in HHR (25) . Our findings indicate an improved HHR of 4 Ϯ 7 beats/min after RD. The beneficial effect on heart rate could be explained by an improvement of autonomic balance after RD. Study limitations. The control group consisted of 9 patients. Therefore, smaller differences between the treatment group and the control group might not reach statistical significance. The study was focused on the intragroup changes after RD, whereas the control group was used to quantify the influence of repeated CPET. Twenty-eight Ukena et al. September 6, 2011 September 6, :1176 Exercise Parameters After Renal Denervation patients of the present study were recruited for the extended Symplicity HTN-2 trial in 2 investigation sites (Homburg/ Saar, Cologne). To avoid selection bias, the remaining 18 patients were included with the same inclusion and exclusion criteria as in the Symplicity HTN-2 trial. All patients were randomized to the control group or the RD group. As is routinely performed in clinical practice, blood pressure was measured noninvasively, which might lower the accuracy of the measurement during exercise; however, this represents daily clinical practice. To minimize any interference, blood pressure was measured by experienced physicians who were blinded to randomization.
Conclusions
This study shows for the first time that RD reduces blood pressure at rest, during physical exercise, and at recovery without affecting the physiological cardiopulmonary response to exercise. Whereas heart rate increase during exercise was not impaired, heart rates at rest and at recovery were significantly lower after RD. Our results support the efficacy and safety of RD in the treatment of resistant hypertension.
